---
title: "Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279892027.md"
description: "Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns"
datetime: "2026-03-20T06:01:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279892027.md)
  - [en](https://longbridge.com/en/news/279892027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279892027.md)
generator: "portal-rs"
---

# Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

### Related Stocks

- [PPBT.US](https://longbridge.com/en/quote/PPBT.US.md)

## Related News & Research

- [Ju Fu Tang Biotech schedules annual general meeting](https://longbridge.com/en/news/296588701.md)
- [Big-Money Move: Major Investor Quietly Boosts Bet on Biotech Player](https://longbridge.com/en/news/296429390.md)
- [PharmAla Biotech says USPTO grants US patent for enantioselective MDMA, MBDB processes](https://longbridge.com/en/news/296608164.md)
- [Biotech Stocks To Consider - August 21st](https://longbridge.com/en/news/296637073.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**